Skip navigation

Accelerate Your Clinical Trials with FARMEA’s GMP Pilot Unit in Angers

 

Did you know? The FARMEA site, part of the FAREVA Group since 2006, offers advanced development capabilities through a GMP pilot unit dedicated to oral, liquid, semi-solid, and nasal dosage forms. This unit supports your projects from the preclinical phase through to clinical trials, providing an environment fully compliant with international regulatory standards (ICH, EMA, FDA).

A dedicated infrastructure for innovation and responsiveness

Designed to reproduce industrial processes on a small scale, the FARMEA pilot unit offers flexible manufacturing capabilities starting from kilolab scale. Technologies include wet granulation, blending, compression, film coating, capsule filling, nasal spray formulation, as well as the production of oral suspensions, creams, ointments, and suppositories.

These versatile and high-performance installations allow for quick adaptation to the specific requirements of each project, from preclinical stages through to Phase III clinical studies. They rely on shared technology platforms, ensuring secure transfer and scale-up across several FAREVA sites (Amboise, Farmea, Farmaclair, Istituto di Angeli, Sigmar…).

A robust and controlled scientific approach

Our development strategy is based on the principles of Quality by Design (QbD) and the use of Design of Experiments (DoE). This methodology promotes a deep understanding of the product and critical process parameters, enabling robust development and efficient transfer to commercial production. It also helps shorten time-to-market and optimize resource allocation.

End-to-end support, from concept to production

FARMEA combines highly qualified teams, recognized regulatory expertise, and state-of-the-art infrastructure to offer an integrated service covering the full product lifecycle:

  • Galenic and analytical development
  • Clinical batch manufacturing
  • Industrial transfer and scale-up
  • Regulatory (CMC) support

-----------

Recently, the pilot unit integrated an Automated Individual Weighing System, addressing the specific needs of Phase I without requiring complex formulation or processing. This innovation significantly reduces API consumption and accelerates clinical trial initiation.

-----------

With these assets, FAREVA reinforces its position as a key player in Contract Development and Manufacturing (CDMO).

For more information, contact us at: pharma@fareva.com 

Discover the Farmea Pilot in video ⬇️